Measuring outcomes in systemic lupus erythematosus clinical trials

References

• Smolen JS, Strand V, Cardiel M et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J. Rheumatol.26(2), 504–507 (1999).
   PubMed Web of Science ®Google Scholar
• Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus9(5), 322–327 (2000).
   PubMed Web of Science ®Google Scholar
• Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann. Rheum. Dis.55(10), 756–760 (1996).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Goldsmith CH, Urowitz MB et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J. Rheumatol.21(8), 1468–1471 (1994).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Goldsmith CH, Urowitz MB et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J. Rheumatol.19(4), 608–611 (1992).
   PubMed Web of Science ®Google Scholar
• Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J. Rheumatol.20(4), 657–660 (1993).
   PubMed Web of Science ®Google Scholar
• Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum.32(9), 1107–1118 (1989).
   PubMed Web of Science ®Google Scholar
• Fortin PR, Abrahamowicz M, Clarke AE et al. Do lupus disease activity measures detect clinically important change? J. Rheumatol.27(6), 1421–1428 (2000).
   PubMed Web of Science ®Google Scholar
• Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J. Rheumatol.27(3), 664–670 (2000).
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford)44(7), 902–906 (2005).
   PubMed Web of Science ®Google Scholar
• Yee CS, Farewell V, Isenberg DA et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford)48(6), 691–695 (2009).
   PubMed Web of Science ®Google Scholar
• Yee CS, Farewell V, Isenberg DA et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum.56(12), 4113–4119 (2007).
   PubMed Web of Science ®Google Scholar
• Vitali C, Bencivelli W, Mosca M, Carrai P, Sereni M, Bombardieri S. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J. Rheumatol.26(2), 498–501 (1999).
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum.35(6), 630–640 (1992).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol.29(2), 288–291 (2002).
   PubMed Web of Science ®Google Scholar
• Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med.353(24), 2550–2558 (2005).
   PubMed Web of Science ®Google Scholar
• Buyon JP, Petri MA, Kim MY et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med.142(12 Pt 1), 953–962 (2005).
   PubMed Web of Science ®Google Scholar
• Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus19(1), 49–51 (2011).
   Google Scholar
• Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus20(1), 67–70 (2011).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J. Rheumatol.27(2), 377–379 (2000).
   PubMed Web of Science ®Google Scholar
• Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann. Rheum. Dis.66(Suppl. 3), III61–III64 (2007).
   PubMedGoogle Scholar
• Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J. Rheumatol.30(9), 1977–1982 (2003).
   PubMed Web of Science ®Google Scholar
• Strand V. Issues in drug development in SLE: clinical trial design, outcome measures, and biomarkers. In: Dubois’ Lupus Erythematosus. Wallace DJ, Hahn BH (Eds). Lippincott Williams & Wilkins, PA, USA (2007).
   Google Scholar
• Yee CS, Farewell VT, Isenberg DA et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford)50(5), 982–988 (2011).
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J. Rheumatol.38(2), 275–284 (2011).
   PubMed Web of Science ®Google Scholar
• Touma Z, Urowitz MB, Fortin PR et al. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: a reliable index for measuring improvement in disease activity. J. Rheumatol.38(5), 868–873 (2011).
   PubMedGoogle Scholar
• Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med.86(7), 447–458 (1993).
   PubMedGoogle Scholar
• Yee CS, Cresswell L, Farewell V et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford)49(9), 1665–1669 (2010).
   PubMed Web of Science ®Google Scholar
• Nived O, Sturfelt G, Liang MH, De Pablo P. The ACR nomenclature for CNS lupus revisited. Lupus12(12), 872–876 (2003).
   PubMed Web of Science ®Google Scholar
• Cresswell L, Yee CS, Farewell V et al. Numerical scoring for the Classic BILAG index. Rheumatology (Oxford)48(12), 1548–1552 (2009).
   PubMed Web of Science ®Google Scholar
• Yee CS, Isenberg DA, Prabu A et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann. Rheum. Dis.67(6), 873–876 (2008).
   PubMed Web of Science ®Google Scholar
• Pope J. The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations. Rheumatology (Oxford)49(9), 1616–1617 (2010).
   PubMedGoogle Scholar
• Wallace DJ, Hobbs K, Houssiau F et al. Epratuzumab (anti-CD22 mAb targeting B-cells) provides clinically meaningful reductions in corticosteroid (cs) use with a favorable safety profile in patients with moderate/severe flaring SLE: results from randomized controlled trials (RCTs). Arthritis Rheum.58, S571 (2008).
   PubMedGoogle Scholar
• Wallace D, Kalunian K, Petri M et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a Phase IIB study. Ann. Rheum. Dis.69(Suppl. 3), 558 (2010).
   Google Scholar
• Kalunian K, Wallace D, Petri M et al. BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: results from EMBLEM, a Phase IIB study. Ann. Rheum. Dis.69(Suppl. 3), 553 (2010).
   Google Scholar
• Petri M, Hobbs K, Gordon C et al. Clinically meaningful improvements with epratuzumab (anti-CD22 mAb targeting B-cells) in patients (pts) with moderate/severe SLE flares: results from two randomized controlled trials. Arthritis Rheum.58, S571 (2008).
   PubMedGoogle Scholar
• Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus10(6), 405–409 (2001).
   PubMed Web of Science ®Google Scholar
• Alarcon GS, Roseman J, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum.41(7), 1173–1180 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang J, Gonzalez LA, Roseman JM, Vila LM, Reveille JD, Alarcon GS. Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX. Lupus19(6), 727–733 (2010).
   PubMed Web of Science ®Google Scholar
• Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46(11), 2924–2927 (2002).
   PubMed Web of Science ®Google Scholar
• Petri MA, Mease PJ, Merrill JT et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum.50(9), 2858–2868 (2004).
   PubMed Web of Science ®Google Scholar
• Vitali C, Bencivelli W, Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin. Exp. Rheumatol.10(5), 541–547 (1992).
   PubMedGoogle Scholar
• Houssiau FA, D’Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis.69(12), 2083–2089 (2010).
   PubMed Web of Science ®Google Scholar
• Ruperto N, Hanrahan L, Alarcon G et al. International consensus for a definition of disease flare in lupus. Lupus20(5), 453–462 (2011).
   PubMed Web of Science ®Google Scholar
• Fortin PR, Ferland D, Clarke AE et al. Activity and damage predicts later flares in lupus. Arthritis Rheum.40, S207 (1997).
   Google Scholar
• Fortin PR, Ferland D, Moore AD. Rates and predictors of lupus flares. Arthritis Rheum.41, S218 (1998).
   Google Scholar
• Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford)42(11), 1372–1379 (2003).
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46(12), 3251–3258 (2002).
   PubMed Web of Science ®Google Scholar
• Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled Phase III trial. Arthritis Rheum.58(8), 2470–2480 (2008).
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum.48(2), 442–454 (2003).
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, Phase 3 trial. Lancet377(9767), 721–731 (2011).
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Zamani O, Wallace DJ et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann. Rheum. Dis.69(Suppl. 3), 74 (2010).
   Google Scholar
• Isenberg DA, Allen E, Farewell V et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann. Rheum. Dis.70(1), 54–59 (2011).
   PubMedGoogle Scholar
• Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N. Engl. J. Med.334(13), 835–840 (1996).
   PubMed Web of Science ®Google Scholar
• Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann. Acad. Med. Singapore36(2), 115–122 (2007).
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Mader R, Langevitz P et al. Quality of life in systemic lupus erythematosus: a controlled study. J. Rheumatol.26(2), 306–309 (1999).
   PubMed Web of Science ®Google Scholar
• Thumboo J, Fong KY, Chan SP et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J. Rheumatol.27(6), 1414–1420 (2000).
   PubMed Web of Science ®Google Scholar
• Saba J, Quinet RJ, Davis WE et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine70(5), 348–351 (2003).
   PubMed Web of Science ®Google Scholar
• Doria A, Rinaldi S, Ermani M et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford)43(12), 1580–1586 (2004).
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Doria A, Salaffi F et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology (Oxford)43(12), 1574–1579 (2004).
   PubMed Web of Science ®Google Scholar
• Alarcon GS, McGwin G Jr, Uribe A et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum.51(3), 465–474 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J. Rheumatol.37(3), 568–573 (2010).
   PubMed Web of Science ®Google Scholar
• Thumboo J, Fong KY, Ng TP et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J. Rheumatol.26(1), 97–102 (1999).
   PubMed Web of Science ®Google Scholar
• Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev. Pharmacoeconomics Outcomes Res.5(3), 317–326 (2005).
   PubMedGoogle Scholar
• Strand V, Aranow C, Cardiel MH et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus12(9), 677–686 (2003).
   PubMed Web of Science ®Google Scholar
• Strand V, Levy RA, Cervera R et al. Belimumab, a BLyS-specific inhibitor, improved fatigue and SF-36 physical and mental component summary scores in patients with SLE: BLISS-76 and -52 studies. Arthritis Rheum.62, S773 (2010).
   Google Scholar
• Hochberg MC, Sutton JD. Physical disability and psychosocial dysfunction in systemic lupus erythematosus. J. Rheumatol.15(6), 959–964 (1988).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus5(3), 190–195 (1996).
   PubMed Web of Science ®Google Scholar
• Colangelo KJ, Pope JE, Peschken C. The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J. Rheumatol.36(10), 2231–2237 (2009).
   PubMedGoogle Scholar
• Burckhardt CS, Archenholtz B, Bjelle A. Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis. J. Rheumatol.20(6), 977–981 (1993).
   PubMed Web of Science ®Google Scholar
• McElhone K, Abbott J, Shelmerdine J et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum.57(6), 972–979 (2007).
   PubMed Web of Science ®Google Scholar
• McElhone K, Castelino M, Abbott J et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J. Rheumatol.37(11), 2273–2279 (2010).
   PubMedGoogle Scholar
• Jolly M, Pickard AS, Wilke C et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann. Rheum. Dis.69(1), 29–33 (2010).
   PubMed Web of Science ®Google Scholar
• Doward LC, McKenna SP, Whalley D et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann. Rheum. Dis.68(2), 196–200 (2009).
   PubMed Web of Science ®Google Scholar
• Leong KP, Kong KO, Thong BY et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford)44(10), 1267–1276 (2005).
   PubMed Web of Science ®Google Scholar
• Jolly M, Pickard AS, Fogg L et al. U.S. patient derived lupus-specific patient reported outcome measure (Lupus-PRO): validity and reliability. Arthritis Rheum.58, S805 (2008).
   Google Scholar
• Furie RA, Petri MA, Wallace DJ et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum.61(9), 1143–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum.61(9), 1168–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Strand V. Patients with active systemic lupus erythematosus (SLE) treated with belimumab improve heath-related quality of life (HRQOL) in a randomized controlled trial (RCT). Arthritis Rheum.54, S277 (2006).
   Google Scholar
• Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J. Rheumatol.26(2), 490–497 (1999).
   PubMed Web of Science ®Google Scholar
• Wekking EM. Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosom. Med.55(2), 219–228 (1993).
   PubMed Web of Science ®Google Scholar
• Strand V, Gordon C, Kalunian K et al. Meaningful improvements in health-related quality of life (HRQoL) with epratuzumab (anti-CD22 mAb targeting B-cells) in patients (pts) with SLE with high disease activity: results from 2 randomized controlled trials (RCTs). Arthritis Rheum.58, S570 (2008).
   Google Scholar
• Petri MA, Lahita RG, Van Vollenhoven RF et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.46(7), 1820–1829 (2002).
   PubMed Web of Science ®Google Scholar
• Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr. Opin. Rheumatol.13(5), 345–351 (2001).
   PubMed Web of Science ®Google Scholar
• Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum.39(3), 363–369 (1996).
   PubMed Web of Science ®Google Scholar
• Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br. J. Rheumatol.35(3), 248–254 (1996).
   PubMedGoogle Scholar
• Gladman DD, Goldsmith CH, Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J. Rheumatol.27(2), 373–376 (2000).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum.40(5), 809–813 (1997).
   PubMed Web of Science ®Google Scholar
• Schiffenbauer J, Simon LS. Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus13(5), 398–405 (2004).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ginzler EM, Gluck OS et al. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. J. Rheumatol.32(4), 616–621 (2005).
   PubMedGoogle Scholar
• Petri M, Barr SG, Buyon J, Davis J, Ginzler E, Kalunian K. RIFLE: responder index for lupus erythematosus. Arthritis Rheum.43, S244 (2000).
   Google Scholar
• Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum.62(5), 1487–1493 (2010).
   PubMedGoogle Scholar
• Bertsias G, Ioannidis JP, Boletis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann. Rheum. Dis.67(2), 195–205 (2008).
   PubMed Web of Science ®Google Scholar
• Petri M, Kasitanon N, Lee SS et al. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum.58(6), 1784–1788 (2008).
   PubMedGoogle Scholar
• Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum.62(1), 222–233 (2010).
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: results of a 12-month exploratory study. Arthritis Rheum.62(10), 3077–3087 (2010).
   PubMed Web of Science ®Google Scholar
• Strand V. A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus. Curr. Rheumatol. Rep.9(6), 427–430 (2007).
   PubMedGoogle Scholar
• Strand V. Lessons learned from clinical trials in SLE. Autoimmun. Rev.6(4), 209–214 (2007).
   PubMedGoogle Scholar
• American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum.50(11), 3418–3426 (2004).
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum.62(1), 211–221 (2010).
   PubMed Web of Science ®Google Scholar
• Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med.353(24), 2539–2549 (2005).
   PubMed Web of Science ®Google Scholar